PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16304046-5 2006 Conversely, separate blockage of the Akt/mTor-signaling pathway was a prerequisite for overcoming apoptosis resistance to VPA/ATRA in FLT3-ITD cells, and primary AML blasts (n = 9). Valproic Acid 122-125 mechanistic target of rapamycin kinase Homo sapiens 41-45 35222122-6 2022 VPA is considered to exert its deleterious effects on the fetal brain through several distinct mechanisms, such as alterations of gamma-aminobutyric acid signaling, the inhibition of histone deacetylase, the disruption of folic acid metabolism, and the activation of mammalian target of rapamycin. Valproic Acid 0-3 mechanistic target of rapamycin kinase Homo sapiens 267-296 34889524-8 2022 Upregulation of TRKB signaling by mediKanren-predicted valproic acid led to subsequent increase of mTor activity. Valproic Acid 55-68 mechanistic target of rapamycin kinase Homo sapiens 99-103 34685502-8 2021 Furthermore, VPA treatment induced autophagy via increased LC3-II levels and decreased p62 expression and mTOR phosphorylation. Valproic Acid 13-16 mechanistic target of rapamycin kinase Homo sapiens 106-110 31911180-6 2020 Knock down of ERBB3 significantly enhanced [neratinib + valproate] lethality, which was associated with greater inactivation of AKT, mTOR, p70 S6K and ERK1/2. Valproic Acid 56-65 mechanistic target of rapamycin kinase Homo sapiens 133-137 32725456-9 2021 VPA regulates autophagy by potentially inhibiting mTORC1, a complex of mTOR, while also hindering inflammatory response. Valproic Acid 0-3 mechanistic target of rapamycin kinase Homo sapiens 50-54 32725456-10 2021 Conclusively, an effective treatment for SCI could lie in the timely regulation of mTOR signaling pathway, and VPA could be the potential drug that improves SCI owing to its propensity to regulate the mTOR signaling pathway. Valproic Acid 111-114 mechanistic target of rapamycin kinase Homo sapiens 201-205 31551670-0 2019 Valproic Acid Enhances Reprogramming Efficiency and Neuronal Differentiation on Small Molecules Staged-Induction Neural Stem Cells: Suggested Role of mTOR Signaling. Valproic Acid 0-13 mechanistic target of rapamycin kinase Homo sapiens 150-154 33356493-0 2020 Valproic Acid Enhanced Apoptosis by Promoting Autophagy Via Akt/mTOR Signaling in Glioma. Valproic Acid 0-13 mechanistic target of rapamycin kinase Homo sapiens 64-68 33356493-5 2020 In addition, VPA activated the Akt/mTOR pathway by decreasing their protein phosphorylation to promote cellular apoptosis. Valproic Acid 13-16 mechanistic target of rapamycin kinase Homo sapiens 35-39 33356493-6 2020 Surprisingly, the mTOR agonist MHY1485, causing a strong elevation of mTOR activity, partially reduced apoptosis ratio, which supposing that the autophagy of VPA is involved in the regulation of apoptosis. Valproic Acid 158-161 mechanistic target of rapamycin kinase Homo sapiens 18-22 33356493-7 2020 These findings suggest that VPA enhanced apoptosis by promoting autophagy via Akt/mTOR signaling in glioma, which could be further evaluated as a reliable therapy for glioma. Valproic Acid 28-31 mechanistic target of rapamycin kinase Homo sapiens 82-86 31551670-8 2019 The VPA-mediated mTOR signaling pathway may enhance reprogramming efficiency and neuronal differentiation. Valproic Acid 4-7 mechanistic target of rapamycin kinase Homo sapiens 17-21 29299126-5 2017 Akt-mTOR signaling was deactivated, whereas acetylation of histone H3 and H4 in RT112res and UMUC-3res increased in the presence of VPA. Valproic Acid 132-135 mechanistic target of rapamycin kinase Homo sapiens 4-8 31010254-3 2019 We determined whether epigenetic modulation by the histone deacetylase (HDAC) inhibitor, valproic acid (VPA), may counteract non-responsiveness to the mTOR inhibitor, temsirolimus, in prostate cancer (PCa) cells. Valproic Acid 89-102 mechanistic target of rapamycin kinase Homo sapiens 151-155 31010254-3 2019 We determined whether epigenetic modulation by the histone deacetylase (HDAC) inhibitor, valproic acid (VPA), may counteract non-responsiveness to the mTOR inhibitor, temsirolimus, in prostate cancer (PCa) cells. Valproic Acid 104-107 mechanistic target of rapamycin kinase Homo sapiens 151-155 24361750-0 2014 Valproic acid enhances Oct4 promoter activity through PI3K/Akt/mTOR pathway activated nuclear receptors. Valproic Acid 0-13 mechanistic target of rapamycin kinase Homo sapiens 63-67 28153093-4 2017 Mechanistic insights into the process of VPA-induced reprogramming revealed that it was dependent on OCT4 promoter activation, which was achieved independently of the PI3K (phosphatidylinositol 3-kinase)/AKT/mTOR (mammalian target of rapamycin) pathway or GSK3beta inhibition but was concomitant with the presence of acetylated histones H3K9 and H3K56, which promote pluripotency. Valproic Acid 41-44 mechanistic target of rapamycin kinase Homo sapiens 208-212 28153093-4 2017 Mechanistic insights into the process of VPA-induced reprogramming revealed that it was dependent on OCT4 promoter activation, which was achieved independently of the PI3K (phosphatidylinositol 3-kinase)/AKT/mTOR (mammalian target of rapamycin) pathway or GSK3beta inhibition but was concomitant with the presence of acetylated histones H3K9 and H3K56, which promote pluripotency. Valproic Acid 41-44 mechanistic target of rapamycin kinase Homo sapiens 214-243 25627160-0 2015 Decreased mTOR signaling pathway in human idiopathic autism and in rats exposed to valproic acid. Valproic Acid 83-96 mechanistic target of rapamycin kinase Homo sapiens 10-14 28494938-0 2017 PI3K/AKT/mTOR Signaling Mediates Valproic Acid-Induced Neuronal Differentiation of Neural Stem Cells through Epigenetic Modifications. Valproic Acid 33-46 mechanistic target of rapamycin kinase Homo sapiens 9-13 27588130-0 2016 Valproic acid induces autophagy by suppressing the Akt/mTOR pathway in human prostate cancer cells. Valproic Acid 0-13 mechanistic target of rapamycin kinase Homo sapiens 55-59 26735433-2 2015 The HDAC (histone deacetylase) inhibitor valproic acid (VPA) interacted synergistically with chemotherapeutic agents to trigger lymphoma cell autophagy, which resulted from activation of AMPK (AMP-activated protein kinase) and inhibition of downstream MTOR (mechanistic target of rapamycin [serine/threonine kinase]) signaling. Valproic Acid 41-54 mechanistic target of rapamycin kinase Homo sapiens 252-256 26735433-2 2015 The HDAC (histone deacetylase) inhibitor valproic acid (VPA) interacted synergistically with chemotherapeutic agents to trigger lymphoma cell autophagy, which resulted from activation of AMPK (AMP-activated protein kinase) and inhibition of downstream MTOR (mechanistic target of rapamycin [serine/threonine kinase]) signaling. Valproic Acid 56-59 mechanistic target of rapamycin kinase Homo sapiens 252-256 24779401-10 2014 VPA treatment up-regulated histone acetylation, but also activated mTOR-Akt signalling. Valproic Acid 0-3 mechanistic target of rapamycin kinase Homo sapiens 67-71 23292124-1 2013 The aim of this study was to elucidate whether the treatment of a prostate carcinoma cell line (LNCaP) and LNCaP-derived tumors with the histone deacetylase (HDAC) inhibitor valproate in combination with the mammalian target of rapamycin (mTOR) inhibitor temsirolimus resulted in synergistic effects on cell proliferation and tumor growth. Valproic Acid 174-183 mechanistic target of rapamycin kinase Homo sapiens 239-243 23866964-4 2013 RESULTS: Co-treatment of VPA and temsirolimus synergistically inhibited the tumor cell growth and triggered the autophagic cell death, with a significant inhibition of MTOR signaling and MYC oncoprotein. Valproic Acid 25-28 mechanistic target of rapamycin kinase Homo sapiens 168-172 21360059-0 2011 Valproic acid modulates superoxide dismutase, uric acid-independent FRAP and zinc in blood of adult epileptic patients. Valproic Acid 0-13 mechanistic target of rapamycin kinase Homo sapiens 68-72 21192952-0 2011 Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001. Valproic Acid 41-54 mechanistic target of rapamycin kinase Homo sapiens 129-133